Table 2.
Baseline characteristics of 20 enrolled patients with COVID-19
| Patient ID | Intervention group (n = 10) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Survivors | Non-survivors | |||||||||
| T1 | T2 | T5 | T7 | T10 | T3 | T4 | T6 | T8 | T9 | |
| Age (years) | 40–49 | 50–59 | 50–59 | 40–49 | 70–79 | 70–79 | 30–39 | 70–79 | 70–79 | 60–69 |
| Gender | 2 | 2 | 1 | 2 | 2 | 1 | 2 | 2 | 1 | 1 |
| Duration of Hospitalization | 10 | 80 | 6 | 9 | 6 | 11 | 4 | 9 | 15 | 16 |
| Weight(kg) | 80 | 95 | 92 | 100 | 87 | 78 | 110 | 73 | 75 | 81 |
| Underlying disease | DM | – | DM, ILD, HTN | IBS | HTN | DM | Sarcoidosis | – | Asthma, HT, HTN | HTN, RA |
| Interval between ICU admission and cell injection (day) | 2 | 1 | 1 | 5 | 2 | 3 | 3 | 2 | 12 | 4 |
| Interval between cell injection and discharge/death (day) | 6 | 78 | 4 | 3 | 3 | 5 | 1 | 6 | 0 | 11 |
| Patient ID | Control group (n = 10) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Survivors | Non-survivors | |||||||||
| C3 | C5 | C7 | C9 | C10 | C1 | C2 | C4 | C6 | C8 | |
| Age (years) | 80–89 | 70–79 | 70–79 | 60–69 | 30–39 | 30–39 | 50–59 | 60–69 | 50–59 | 70–79 |
| Gender | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Duration of Hospitalization | 7 | 6 | 28 | 7 | 7 | 11 | 9 | 3 | 6 | 9 |
| Weight(kg) | 65 | 70 | 75 | 85 | 90 | 104 | 90 | 69 | 80 | 100 |
| Underlying disease | – | DM, HTN | Sarcoidosis, asthma, Liver Hemangioma | – | – | – | CKD | DM, HTN | HTN,DM | DM, HTN |
| Interval between ICU admission and cell injection (day) | – | – | – | – | – | – | – | – | – | – |
| Interval between cell injection and discharge/death (day) | – | – | – | – | – | – | – | – | – | – |
DM DiabetesMellitus, ILD Interstitial Lung Disease, HTN Hypertension, IBS Irritable Bowel Syndrome, HT Hypothyroidism, RA Rheumatoid Arthritis, CKD Chronic Kidney Disease